| (Values in U.S. Thousands) | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 | Mar, 2020 |
| Sales | 100 | 200 | 70 | 130 | 140 |
| Sales Growth | -50.00% | +185.71% | -46.15% | -7.14% | unch |
| Net Income | -1,380 | -1,000 | -1,350 | -1,700 | -1,000 |
| Net Income Growth | -38.00% | +25.93% | +20.59% | -70.00% | unch |
Cardax Inc (CDXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cardax, Inc. is a development stage life sciences company. It develops nutraceutical and pharmaceutical products that provide anti-inflammatory benefits of steroids or NSAIDS. The Company primarily focuses on developing astaxanthin technologies for unmet medical needs. Cardax, Inc. is based in Honolulu, Hawaii.
Fiscal Year End Date: 12/31